CN108926559A - Wedelolactone is preparing the application in anti-candida albicans drug - Google Patents
Wedelolactone is preparing the application in anti-candida albicans drug Download PDFInfo
- Publication number
- CN108926559A CN108926559A CN201810536994.7A CN201810536994A CN108926559A CN 108926559 A CN108926559 A CN 108926559A CN 201810536994 A CN201810536994 A CN 201810536994A CN 108926559 A CN108926559 A CN 108926559A
- Authority
- CN
- China
- Prior art keywords
- candida albicans
- wedelolactone
- drug
- cell
- mycelia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
The invention discloses wedelolactones to prepare the application in anti-candida albicans drug.Inventor with Candida albicans be for trying object, screening efficiently, low toxicity, be not likely to produce the compound of drug resistance, discovery wedelolactone is to the adhesiveness of Candida albicans, mycelia formation rate, biofilm formation and pathogenic has good inhibiting effect.Moreover, compound toxicity itself is smaller, the growth of human cell is not influenced；The normal growth of Candida albicans is not influenced simultaneously, show the compound to the effect of albicans strain not mainly by kill Candida albicans, but by inhibiting the adhesiveness of Candida albicans, mycelia to be formed, biofilm formation and pathogenic, therefore be not likely to produce drug resistance.This has a good application prospect in terms of the exploitation of the exploitation of novel antifungal drugs, especially anti-candida albicans infection medicine.
Description
Technical field
The invention belongs to biomedicine technical fields, in particular to wedelolactone is in preparing anti-candida albicans drug
Application.
Background technique
Candida albicans (Candida albicans) is the fungal disease of the wide-scale distribution in the mankind, is a kind of important
Opportunistic fungus, it will usually cause acute, subacute or chronic infection, and the most important disease of hospital acquired infections now
One of original.In healthy human body mucous membrane surface, such as oral cavity, enteron aisle, Candida albicans will not usually cause disease, but in immune system
It is damaged or inhibits in patient body, in chemotherapy patients, organ transplant patients or aids patient, serious system can be caused
Sexuality dye, lethality are up to 40%.
Clinically antifungal species are limited at present, and wherein azole drug (Fluconazole) is widely used, and Fluconazole is
By inhibiting fungi duplication to play antibacterial effect, but with the abuse of antibiotic, the phenomenon that drug resistance, is increasingly severe.
Summary of the invention
The purpose of the present invention is to overcome the shortcomings of the existing technology and deficiency, provides wedelolactone and is preparing anti-white thought
Application in pearl bacterium drug.
The purpose of the invention is achieved by the following technical solution：Wedelolactone is in preparing anti-candida albicans drug
Using.
No. CAS of the wedelolactone is 524-12-9, and structural formula is as follows：
Specifically, the anti-candida albicans refer to the adhesiveness for inhibiting Candida albicans, mycelia formation, biomembrane shape
At, pathogenic (to the toxicity action of Candida albicans).
The anti-candida albicans drug includes the drug for preventing and/or treating candida albicans infection, and
For preventing and treating the microbial infectious disease medicament of Candida albicans.
The invention has the advantages that：
Yeast-mycelia dimorphism is the distinctive characteristic of Candida albicans.Free yeast state is during infection for host
Be do not have it is virose, it is main to exercise the effect for being adhered to receptor tissue, then carry out from yeast state to the transformation of mycelia state to promote
Into invading, enters infected tissue by cause of disease of mycelia state later, further play toxic effect.Yeast-mycelia Morphological Transitions
It is the significant process that Candida albicans plays virulence.Therefore, the present invention is peculiar from Candida albicans in the research work of early period
Yeast-mycelia dimorphism start with, pointedly screening efficiently, low toxicity, be not likely to produce the compound of drug resistance.Then with white
Candida albicans (Candida albicans) is to have investigated the wedelolactone of the invention screened to Candida albicans for trying object
Adhesiveness, mycelia formation rate, the influence of biofilm formation and cytotoxicity, it is therefore an objective to pass through detection wedelolactone pair
The interference of Candida albicans virulence formative factor further influences the dissemination of Candida albicans.The results show that in wedelia chinensis
Ester does not influence the growth of Candida albicans, is formed to the adhesiveness of Candida albicans, mycelia, biofilm formation and pathogenic
With good inhibiting effect, show wedelolactone to the effect of albicans strain not mainly by kill white
Candida albicans, but it is pathogenic by inhibiting the adhesiveness of Candida albicans, mycelia to be formed, therefore it is not likely to produce drug resistance.Moreover,
Wedelolactone toxicity itself is smaller, does not influence the growth of human cell.Therefore, wedelolactone is in novel antifungal drugs
It is had a good application prospect in terms of the exploitation of exploitation, especially anti-candida albicans infection medicine
Therefore, wedelolactone prepare anti-candida albicans infection drug in application, and preparation prevention and/
Or the application in the drug of the treatment microbial infectious diseases of Candida albicans, it should all be within protection scope of the present invention.
Detailed description of the invention
Fig. 1 is influence result figure of the wedelolactone to Candida albicans in terms of A549 cytopathic；Wherein, scheme
It (A) is cytotoxicity testing result figure of final concentration of 100 μM of the wedelolactone to A549 cell；Scheming (B) is various concentration
Wedelolactone to the testing result figure after Candida albicans infected cell.
Fig. 2 is influence result figure of the wedelolactone to Candida albicans growth rate；Wherein, DMSO is as control；Number
According to 3 duplicate average results of biology are shown, error bar reflects standard deviation.
Fig. 3 is that final concentration of 100 μM of wedelolactone generates the microscope photo figure inhibited to Candida albicans mycelia；
Wherein, provided with DMSO control, final concentration of 100 μM of BDSF control, the control of final concentration of 100 μM of Fluconazole.
Fig. 4 is the inhibiting rate measurement result figure that final concentration of 100 μM of wedelolactone forms Candida albicans mycelia；
The average result of 4 secondary pollutants experiment is shown in this data, and error bar reflects standard deviation.
Fig. 5 is influence result figure of the wedelolactone to Candida albicans adhesiveness；Wherein, DMSO, BDSF are as control；
4 duplicate average results of biology are shown in data, and error bar reflects standard deviation.
Fig. 6 is influence result figure of the wedelolactone to Candida albicans biofilm formation；Wherein, DMSO, BDSF conduct
Control；8 duplicate average results of biology are shown in data, and error bar reflects standard deviation.
Specific embodiment
Present invention will now be described in further detail with reference to the embodiments and the accompanying drawings, but embodiments of the present invention are unlimited
In this.
Unless stated otherwise, the present invention uses reagent, method and apparatus for the art conventional reagent, method and are set
It is standby.
Unless stated otherwise, following embodiment agents useful for same and material are commercially available.
The detection of 1 wedelolactone antibacterial activity of embodiment
1, test method：
(1) activation of albicans strain：
Candida albicans reference culture SC5314 is activated into (tryptone 10g/L, yeast extract in LB solid medium
5g/L, NaCl 10g/L, agar 15g/L), it is placed in 30 DEG C of incubator overnight incubations.
(2) influence of the wedelolactone to albicans strain SC5314 cytotoxicity：
(a) recovery and culture of Non-small cell lung carcinoma cell line A549 cell：The A549 cell of freeze thawing is transferred to and is contained
In the DMEM culture medium (Gibco company) of 10% (v/v) FBS, 37 DEG C, 5%CO2Under the conditions of be incubated overnight.
(b) A549 cell prepares：A549 cell is in the high glucose medium DMEM containing 10% fetal calf serum, with 1.5 × 104
The cell concentration in a/hole overnight incubation in 96 orifice plates.When being covered with 96 orifice plate bottom 80% to cell, culture solution is discarded,
It is cleaned cell 3 times with 1 × PBS.
(c) Candida albicans prepares：The fresh SC5314 of picking is inoculated in GMM culture solution, under the conditions of 30 DEG C, 200rpm
Shaken cultivation is stayed overnight；OD is adjusted to cell maintenance medium (DMEM containing 1%FBS)600=1.0, then 10 are diluted with cell maintenance medium
(≈ 10 again8Cfu/mL), bacteria-containing cell maintenance medium is obtained.
(d) cytotoxicity bioassay：
A) wedelolactone, the wedelolactone mother liquor that preparation concentration is 2mM are dissolved with DMSO.
B) toxicity action of the measurement wedelolactone itself to cell：Wedelolactone mother liquor is diluted to 1mM with DMSO,
It is added in cell maintenance medium, final concentration of 100 μM of wedelolactone, obtains test fluid A；Meanwhile control group is set, i.e., with phase
The DMSO of same volume replaces wedelolactone mother liquor, obtains test fluid B.By 100 holes μ L/, test fluid A and test fluid B is distinguished
It is added in ready A549 cell, is placed in 37 DEG C, 5%CO28h, 4 repetitions of every processing are cultivated in cell incubator.
C) wedelolactone and Candida albicans are measured to the toxicity action of cell：Wedelolactone mother liquor is dilute with DMSO
Be interpreted into concentration be 1mM, 500 μM, 250 μM, 125 μM of dilute liquid medicine, then by wedelolactone dilution respectively with it is bacteria-containing
Cell maintenance medium by volume 1:9 proportion mixing, obtain test fluid C, final concentration of the wedelolactone in test fluid C is respectively
100 μM, 50 μM, 25 μM, 12.5 μM, in test fluid C, the volume content of DMSO is identical；Setting only adds DMSO (diformazan simultaneously
Base sulfoxide), BDSF (cis-2-dodecenoic acid, along 2- dodecenoic acid, the virtuous Chemical Industry Science Co., Ltd in Shanghai) and
FLC (Fluconazole) is as control, wherein with DMSO and bacteria-containing cell maintenance medium by volume 1:9 proportion mixing, are tested
Liquid D；With BDSF mother liquor (dissolving to obtain with DMSO, concentration 1mM) and bacteria-containing cell maintenance medium by volume 1:9 proportions are mixed
It closes, obtains test fluid E；Volume is pressed with Fluconazole mother liquor (dissolving to obtain with DMSO, concentration 1mM) and bacteria-containing cell maintenance medium
Than 1:9 proportion mixing, obtain test fluid F.By 100 holes μ L/, test fluid C~F is separately added into ready A549 cell,
It is placed in 37 DEG C, 5%CO28h, 4 repetitions of every processing are cultivated in cell incubator.
D) referring to Promega company CytoToxNonRadioactive Cytotoxicity Assay operating method
Cell LDH activity is measured, then handles data with GraphPad Prism 6.
(3) wedelolactone measures albicans strain SC5314 growth effect：
Picking bacterial strain SC5314 single colonie is inoculated in GMM culture solution (6.7g/L YNB, 0.2% glucose), 30 DEG C,
200rpm shaken cultivation is stayed overnight, and bacterium solution OD is measured600, bacterium solution is diluted to OD with GMM600=0.05.It is with concentration by the bacterium solution
The wedelolactone medical fluid of 1mM by volume 9:1 mixing, is added in 100 orifice plates by the amount in 300 holes μ L/, each processing setting
3 repetitions, while the processing for only adding DMSO is set.It is placed in growth curve analyzer, 30 DEG C, 200rpm, every 2h measurement is primary
OD600It is worth, observation experiment after 2d is as a result, GraphPad Prism 6 handles data.
(4) influence of the wedelolactone to albicans strain SC5314 mycelia：
SC5314 bacterial strain on picking LB solid plate, is inoculated in GMM culture solution, and 30 DEG C, 200rpm shaken cultivation mistake
Night measures bacterium solution OD600, bacterium solution is diluted to OD600=0.1 with GMM.It takes 500 μ L bacterium solutions in 1.5mL EP pipe, Peng is added
Qi chrysanthemum lactone, final concentration of 100 μM；DMSO, BDSF (B.cenocepaciadiffusible signal are set simultaneously
Factor is formed with good inhibiting effect to SC5314 mycelia) it is respectively positive, negative control.Concussion mixes, and is placed in 37 DEG C
It is incubated in water-bath, after 6h, is centrifuged 5000rpm, 10min, abandons supernatant, 40 μ L GMM culture solutions are added, thallus is resuspended, in Zeiss
The formation of 2 microscopically observation mycelia of Axioplan takes different visual field shooting photos.
(5) influence of the wedelolactone to albicans strain SC5314 adhesiveness：
(a) recovery and culture of A549 cell：The A549 cell of freeze thawing is transferred to the DMEM culture medium containing 10%FBS
In (Gibco company), 37 DEG C, 5%CO2Under the conditions of be incubated overnight.
(b) A549 cell prepares：A549 cell is in the high glucose medium DMEM containing 10% fetal calf serum, with 0.5 × 103
The cell concentration in a/hole overnight incubation in 96 orifice plates.When being covered with 96 orifice plate bottom 80% to cell, culture solution is discarded,
It is cleaned cell 3 times with 1 × PBS.
(c) the SC5314 bacterial strain on picking LB solid plate is inoculated in GMM culture solution (6.7g/L YNB, 0.2% grape
Sugar) in, 30 DEG C, 200rpm shaken cultivation is stayed overnight, and measures bacterium solution OD600.Then adjusted with cell maintenance medium (DMEM containing 1%FBS)
Bacterium solution is diluted to OD by section600=0.5.By wedelolactone mother liquor with DMSO be diluted to concentration be 1mM, 500 μM, 250 μM, 125
μM dilute liquid medicine, then by wedelolactone dilution respectively with bacteria-containing cell maintenance medium by volume 1:9 proportion mixing,
Concussion mixes, and obtains test fluid G, final concentration of the wedelolactone in test fluid G is respectively 100 μM, 50 μM, 25 μM, 12.5 μ
M.Step (b) is added by 100 holes μ L/ to have cultivated in 96 orifice plates of cell, 4 repetitions are arranged in each processing；Setting only adds simultaneously
The processing of DMSO and BDSF, wherein with DMSO and bacteria-containing cell maintenance medium by volume 1:9 proportion mixing, obtain test fluid
H；With BDSF mother liquor (dissolving to obtain with DMSO, concentration 1mM) and bacteria-containing cell maintenance medium by volume 1:9 proportion mixing,
Obtain test fluid I.96 orifice plates are statically placed in 37 DEG C and are incubated for, culture solution is discarded after 1.5h, every hole is added 100 μ L concentration and is
The crystal violet solution of 0.1% (w/v), room temperature act on 45min.Crystal violet is discarded, and with ice ddH2O is washed 10 times, and 100 μ L are added
Concentration is the ethanol solution of percent by volume 75%, is placed at room temperature for 30 minutes, measures OD590, with 6 software of GraphPad Prism
Handle data.
(6) influence of the wedelolactone to albicans strain SC5314 biofilm formation：
SC5314 bacterial strain on picking LB solid plate is inoculated in SDA culture solution (40g maltose, 10g peptone, distillation
Water is settled to 1L, adjusts pH to 6.0 ± 0.2), 30 DEG C, 200rpm shaken cultivation stay overnight, measure bacterium solution OD600.Then cultivated with SDA
Bacterium solution is diluted to OD by liquid600=0.1, obtain bacteria-containing SDA culture solution.Wedelolactone mother liquor is diluted to concentration with DMSO
For 1mM, 500 μM, 250 μM, 125 μM of dilute liquid medicine, then by wedelolactone dilution respectively with bacteria-containing SDA culture solution
By volume 1:9 proportion mixing, concussion mix, and obtain test fluid J, final concentration of the wedelolactone in test fluid J is respectively
100μM,50μM,25μM,12.5μM.It is added in 96 orifice plates by 100 holes μ L/, 8 repetitions are arranged in each processing, while being arranged only
Add DMSO and only adds the processing of BDSF (final concentration of 100 μM of BDSF).96 orifice plates are statically placed in 37 DEG C and are incubated for, are abandoned after 8h
Fall culture solution, 100 μ L, 0.1% crystal violet is added, room temperature acts on 45min.Crystal violet is discarded, and with ice ddH2O is washed 10 times,
100 μ L, 75% ethyl alcohol is added, is placed at room temperature for 30 minutes, measures OD590, with 6 software data processing of GraphPad Prism.
2, experimental result
(1) wedelolactone has certain inhibiting effect to the virulence of albicans strain SC5314
We detect the toxicity of cell by detecting the burst size of LDH, when detecting the cytotoxicity of Candida albicans,
We will joined the LDH burst size of DMSO group as 100%, and thus carrys out specification the LDH of wedelolactone groups is added in other
Releasing ratio.As a result as shown in Figure 1,4 duplicate average results of biology are shown in data, error bar reflects standard
Difference.
Cytotoxicity experimental result is shown, is control with DMSO, under conditions of no Candida albicans, wedelolactone
There is no toxicity to cell, as shown in Fig. 1 (A).
And under conditions of adding Candida albicans SC5314, it is the positive with DMSO, BDSF is negative control, Fig. 1 (B) display
Wedelolactone has certain protective role to infecting for cell in inhibition bacterial strain SC5314, in 100 μM of concentration, Candida albicans
The virulence of bacterium is reduced to 10%.
(2) wedelolactone does not influence the growth of albicans strain SC5314
As a result as shown in Fig. 2, being control with DMSO, to albicans strain when the concentration of wedelolactone is 100 μM
The growth of SC5314 does not influence substantially.This result shows that wedelolactone to the effect of albicans strain SC5314 not
It is to kill bacterium, therefore be not likely to produce drug resistance.
(3) wedelolactone inhibits the formation of albicans strain SC5314 mycelia
Fig. 3 is the photo figure that the mycelia observed under the microscope is formed.The inhibiting rate that mycelia is formed is calculated by photo figure：
One sample is clapped 3 and is taken (3 pictures, 3 repetition values), and the mycelia on number photo, the mycelia formed with DMSO is 100%.As a result
As shown in figure 4, wedelolactone has an apparent inhibiting effect for Candida albicans SC5314, inhibiting rate reached 85% with
On.
(4) wedelolactone inhibits the adhesiveness of albicans strain SC5314
As shown in figure 5, using DMSO as reference, through final concentration of 100 μM of wedelolactone treated Candida albicans
Adhesiveness on polystyrene, reduces 10.7% or so.Show that wedelolactone is shown to Candida albicans
The adhesiveness of SC5314 has certain inhibiting effect.
(5) influence of the wedelolactone to albicans strain SC5314 biofilm formation：
As shown in fig. 6, using DMSO as reference, through final concentration of 100 μM of wedelolactone treated Candida albicans
Biofilm formation on polystyrene, reduces 98.7% or so.Show that wedelolactone is shown to Candida albicans
The biofilm formation of SC5314 has inhibiting effect.
The above embodiment is a preferred embodiment of the present invention, but embodiments of the present invention are not by above-described embodiment
Limitation, other any changes, modifications, substitutions, combinations, simplifications made without departing from the spirit and principles of the present invention,
It should be equivalent substitute mode, be included within the scope of the present invention.
Claims (3)
1. wedelolactone is preparing the application in anti-candida albicans drug.
2. wedelolactone according to claim 1 is preparing the application in anti-candida albicans drug, it is characterised in that：
The anti-candida albicans drug is with inhibiting the adhesiveness of Candida albicans, mycelia formation, biofilm formation, pathogenic
Drug.
3. wedelolactone according to claim 1 is preparing the application in anti-candida albicans drug, it is characterised in that：
The anti-candida albicans drug is drug for preventing and/or treating candida albicans infection, and for preventing and
Treat one or both of microbial infectious disease medicament of Candida albicans.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810536994.7A CN108926559A (en) | 2018-05-30 | 2018-05-30 | Wedelolactone is preparing the application in anti-candida albicans drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810536994.7A CN108926559A (en) | 2018-05-30 | 2018-05-30 | Wedelolactone is preparing the application in anti-candida albicans drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108926559A true CN108926559A (en) | 2018-12-04 |
Family
ID=64449692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810536994.7A Pending CN108926559A (en) | 2018-05-30 | 2018-05-30 | Wedelolactone is preparing the application in anti-candida albicans drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108926559A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109820848A (en) * | 2019-04-04 | 2019-05-31 | 南通大学附属医院 | The new application of wedelolactone |
| CN109820849A (en) * | 2019-02-26 | 2019-05-31 | 青岛大学附属医院 | Wedelolactone is preparing the application in the drug for treating fungal keratitis |
| CN115074313A (en) * | 2022-06-29 | 2022-09-20 | 五邑大学 | Application of wedelolactone in preparation of product for promoting embryonic development |
-
2018
- 2018-05-30 CN CN201810536994.7A patent/CN108926559A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109820849A (en) * | 2019-02-26 | 2019-05-31 | 青岛大学附属医院 | Wedelolactone is preparing the application in the drug for treating fungal keratitis |
| CN109820849B (en) * | 2019-02-26 | 2022-02-22 | 青岛大学附属医院 | Application of wedelolactone in preparation of medicine for treating fungal keratitis |
| CN109820848A (en) * | 2019-04-04 | 2019-05-31 | 南通大学附属医院 | The new application of wedelolactone |
| CN115074313A (en) * | 2022-06-29 | 2022-09-20 | 五邑大学 | Application of wedelolactone in preparation of product for promoting embryonic development |
| CN115074313B (en) * | 2022-06-29 | 2023-10-17 | 五邑大学 | Application of wedelolactone in preparation of embryo development promoting product |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021109549A1 (en) | Joint application of quercetin and antibacterial medicament | |
| CN108926559A (en) | Wedelolactone is preparing the application in anti-candida albicans drug | |
| Othman et al. | Isolation and identification Candida spp from urine and antifungal susceptibility test | |
| CN108498784A (en) | Application of the Radix pseudostellariae cyclic peptides B in preparing anti-candida albicans drug | |
| CN108785291A (en) | Application of the hypocrellin in the product for preparing anti-candida albicans | |
| WO2023019924A1 (en) | Use of caffeol or derivative thereof in preparation of anti-candida-albicans drug or anti-candida-albicans daily articles | |
| CN113730384B (en) | Application of 4-methoxy phenanthrene-2, 5-diol in preparation of candida albicans resistant medicines or candida albicans resistant daily necessities | |
| CN108743575A (en) | Application of the butyl p-hydroxybenzoate in preparing anti-candida albicans drug | |
| CN109843289B (en) | Diaryl sulfur group compound for resisting candida albicans, preparation and application thereof | |
| CN108653277A (en) | Application of the kawain derivative in preparing anti-candida albicans drug | |
| Zhang et al. | Alnustone inhibits Streptococcus pneumoniae virulence by targeting pneumolysin and sortase A | |
| CN108836976A (en) | Ginsenoside RG5 is preparing the application in anti-candida albicans drug | |
| CN109496211B (en) | Piperazine derivative for resisting candida albicans as well as preparation method and application thereof | |
| CN108853120A (en) | Peimisine is preparing the application in anti-candida albicans drug | |
| CN108524491A (en) | Application of the Hydroxygenkwanin in preparing anti-candida albicans drug | |
| CN108578400B (en) | Application of lysionotin in preparation of anti-candida albicans drugs | |
| BR112021006569A2 (en) | macrocyclic compounds and uses thereof | |
| Rathi et al. | In-Vitro Anti-fungal Screening of Embelia ribes Plant Extract through EUCAST Method | |
| CN110613720B (en) | Application of veratrine in preparation of medicine for preventing and treating candida albicans infection | |
| CN105168139B (en) | Application of the silver-colored bag palladium nanometer formulation in anti-Cryptococcus infections medicine is prepared | |
| RU2315113C2 (en) | Method for diagnosis of sensitivity of mycobacterium tuberculosis to antituberculosis preparations | |
| Rathi et al. | Antifungal activity of Embelia ribes plant extracts | |
| CN114652731B (en) | Application of tannic acid in preparation of medicine for preventing and treating African swine fever | |
| CN114209835B (en) | Medicine for treating candida infection diseases | |
| Daruliza et al. | Anti-Candida activity and brine shrimp toxicity assay of Ganoderma boninense |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181204 |
|
| RJ01 | Rejection of invention patent application after publication |